BEFIRADOL
Medication-Induced Dyskinesia
Neurolixis SASSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Medication-Induced Dyskinesia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEVODOPA Sumitomo Pharma Co., Ltd. | Phase 4 | A |
carbidopa AbbVie (prior sponsor, Abbott) | Phase 4 | BBB |
Amantadine Adamas Pharmaceuticals, Inc. | Phase 3 | BBB |
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- Novartis Pharmaceuticals | Phase 2 | BBB |
Emd 128130 EMD Serono | Phase 3 | BBB |
View all 29 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →